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Abstract
Endogenous airway acidification, as assessed by exhaled breath condensate (EBC) pH, is present in patients with
stable COPD. The aim of this study was to measure EBC pH levels in a large cohort of COPD patients and to
evaluate associations with functional parameters according to their smoking status.
EBC was collected from 161 patients with stable COPD and 112 controls (current and ex-smokers). EBC pH was
measured after Argon deaeration and all subjects underwent pulmonary function testing.
EBC pH was lower in COPD patients compared to controls [7.21 (7.02, 7.44) vs. 7.50 (7.40, 7.66); p < 0.001] and ex-
smokers with COPD had lower EBC pH compared to current smokers [7.16 (6.89, 7.36) vs 7.24 (7.09, 7.54), p = 0.03].
In ex-smokers with COPD, EBC pH was lower in patients with GOLD stage III and IV compared to patients with
stage I disease (p = 0.026 and 0.004 respectively). No differences were observed among current smokers with
different disease severity. EBC pH levels in ex-smokers were associated with static hyperinflation (as expressed by
IC/TLC ratio), air trapping (as expressed by RV/TLC ratio) and diffusing capacity for carbon monoxide, whereas no
associations were observed in current smokers.
Endogenous airway acidification is related to disease severity and to parameters expressing hyperinflation and air
trapping in ex-smokers with COPD. The possible role of EBC pH in COPD needs to be further evaluated in
longitudinal studies.
Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation that is not fully reversible, is
usually progressive, and is associated with an abnormal
inflammatory response of the lungs in response to noxious
particles and gases [1]. Although spirometry has been used
as the gold-standard for the diagnosis and classification of
COPD [1] as well as the marker for the description of dis-
ease severity, and progression [2], markers that express
hyperinflation and low diffusing capacity seem to be also
related to patients’ mortality and health related quality of
life [3]. Although many biomarkers have been proposed
for the characterization of disease severity in COPD, none
has been proven to be useful for that purpose yet [2].
It has been postulated that acidification of the exhaled
air may be a surrogate marker of airway inflammation in
COPD [4]. In support of this hypothesis we have
previously shown an association of EBC pH with sputum
neutrophils and markers of oxidative stress in exhaled air
[5]. EBC pH has also been previously shown to be asso-
ciated with FEV1 [5]. However, according to our knowl-
edge, no study has evaluated the association of EBC pH
with functional and clinical parameters that are relevant to
clinical practice in a large cohort of patients with COPD.
The aim of the present study was to evaluate EBC pH
levels in a large cohort of COPD patients with different
disease severity and to compare them with smoking con-
trols matched for age, gender and smoking habit. Asso-
ciations of EBC pH values with functional parameters,
including parameters expressing static hyperinflation and
air-trapping, were evaluated. Finally, those associations
were further analyzed according to the smoking status of
COPD patients (current vs. ex-smokers).
Materials and methods
Study Subjects
From January 2008 to December 2009 we enrolled 161
consecutive COPD outpatients with mild to very severe
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subjects (current and ex-smokers). All COPD study sub-
jects had stable disease for the last 8 weeks. All subjects
were evaluated in the outpatient COPD clinics of two ter-
tiary University hospitals (University Hospital of Larissa
and Attikon University Hospital of Athens). We excluded
patients with other coexisting respiratory disorders, as
well as patients with a history of smoking cessation <6
months, in order to stratify subjects as either current or
ex-smokers. All patients provided a detailed history upon
arrival, and underwent physical examination, exhaled
breath condensate (EBC) collection and pulmonary func-
tion testing and, finally, bronchodilation testing and post-
bronchodilation spirometry. Control subjects were other-
wise healthy current or ex-smokers attending the outpati-
ent clinics of the two hospitals for preoperative
evaluation for elective minor surgery. None of our sub-
jects had clinical history suggestive of gastroesophageal
reflux disease. All subjects did not smoke or eat/drink
any meal for at least 2 hours before collection. The study
protocol was approved by the local ethics committees
and all patients provided written informed consent.
Pulmonary Function Tests
Pulmonary function tests (PFTs) were performed with a
commercially available system (Master Screen, Erich Jae-
ger GmbH, Wuerzburg, Germany) and included post-
bronchodilator forced expiratory volume in one second
(FEV1), FVC, FEV1/FVC ratio, total lung capacity (TLC),
residual volume (RV), inspiratory capacity (IC), and dif-
fusing capacity for carbon monoxide (DLCO). Diffusing
capacity for carbon monoxide (DLCO) and diffusing
capacity for carbon monoxide adjusted for alveolar
volume (DLCO/VA) were assessed by a single breath
method with the patient in the sitting position. Lung
function measurements were expressed as percentages
of predicted values. Tests were performed according to
the American Thoracic Society guidelines [6] by two
experienced technicians, who were not aware of the
EBC pH measurements, in order to ensure consistency
of results.
Exhaled Breath condensate collection and pH
measurement
Exhaled breath condensate (EBC) was collected using a
commercially available condenser (EcoScreen; Viasys,
Hoechberg, Germany) according to the ATS/ERS
recommendations [7]. Subjects rinsed their mouths with
distilled water and were asked to perform tidal breathing
for 20 min through a mouthpiece wearing a nose clip,
while sitting comfortably on a chair. Approximately 2
mL of condensate were collected EBC pH was measured
right after EBC collection as previously described [5,8].
Stable pH was achieved after deaeration with an inert
gas (argon, 350 ml/minute for 10 minutes) and was
measured using a commercially available pH meter
(Model 3510, Jenway, Essex, UK).
Statistical analysis
Data are expressed as mean ± standard deviation (SD)
or as median (interquartile ranges) for normally distrib-
uted and skewed data, respectively. Normality of distri-
butions was checked with Kolmogorov-Smirnov test.
Comparisons between COPD patients were performed
with Kruskal-Wallis tests for skewed variables and with
one way analysis of variance (ANOVA) for normally dis-
tributed variables, with appropriate post-hoc tests
(Dunn’s and Bonferroni, respectively). Correlations were
assessed using Spearman’s rank correlation coefficient
for skewed variables and Pearson’s correlation coeffi-
cient for normally distributed variables. For the compar-
isons of EBC pH levels among groups with different
pulmonary function tests severity, the study participants
were divided to quartiles according to their results in
the pulmonary function tests, with the exception of IC/
TLC ratio where a previously reported cut-off point of
≤0.25 [9] was used for the expression of severe hyperin-
flation. P values < 0.05 were considered statistically sig-
nificant. Statistical analysis was performed using the
SPSS 16 statistical package (SPSS, Chicago, IL). Graphs
were created using GraphPad Prism 5 (GraphPad Soft-
ware Inc, La Jolla, CA, USA).
Results
Demographic characteristics of the study subjects are
shown in Table 1. Patients with COPD and controls did
not differ in age, gender and smoking habit; however
ex-smokers with COPD had significantly lower FEV1,
FEV1/FVC and DLCO compared to current smokers.
EBC pH in Patients with Different Levels of COPD Severity
EBC pH was significantly lower in patients with COPD
compared to control subjects [7.21 (7.02, 7.44) vs. 7.50
(7.40, 7.66); p < 0.001]. Ex-smokers with COPD had
lower EBC pH compared to current smokers with
COPD [7.16 (6.89, 7.36) vs. 7.24 (7.09, 7.54), p = 0.03;
Figure 1]. In ex-smokers with COPD, EBC pH was
lower in patients with severe and very severe disease
(GOLD stage III and IV) compared to patients with
mild (GOLD stage I) disease 7.16 (6.70, 7.29) and 6.98
(6.45, 7.07) vs. 7.86 (7.36, 8.02), p = 0.026 and 0.004
respectively (Figure 2A)]. However, no differences were
observed among COPD current smokers with different
disease severity (Figure 2B).
EBC pH Correlations
EBC pH presented significant correlations with several
parameters of the pulmonary function tests of the
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present only in the group of ex-smokers and were
absent in the group of current smokers (Table 2).
Associations of EBC pH with Static Hyperinflation and Air-
Trapping
EBC pH was significantly lower in COPD patients with
severe hyperinflation, as expressed by an IC/TLC ratio
≤0.25 [7.19 (6.93, 7.32) vs. 7.23 (7.05, 7.53) respectively;
p = 0.005. This difference was still present in ex-smo-
kers [7.12 (6.89, 7.32) vs. 7.20 (7.00, 7.59); p = 0.024]
whereas no statistical significant difference was observed
in current smokers. EBC pH differed significantly
between COPD patients with different severity of air
trapping, as expressed by the RV/TLC quartiles (p <
0.001, Table 3). However, post hoc analysis revealed sta-
tistically significant difference only between the first and
the fourth quartile (p < 0.001). This difference was
observed in ex-smokers (p = 0.006), but not in current
smokers (p = 0.398).
Associations of EBC pH with Diffusing Capacity for
Carbon Monoxide
EBC pH was significantly lower in patients with lower
DLCO (p = 0.0006, Table 4). This difference was present
in ex-smokers (p = 0.004) but not in current smokers (p
= 0.82).
Discussion
In the present study we have shown that EBC pH levels
are lower in patients with COPD compared to age and
gender matched controls and are related to disease
severity, as expressed by GOLD stages, especially in ex-
smokers. EBC pH levels are additionally associated with
the presence of static hyperinflation (as expressed by the
IC/TLC ratio), air trapping (as expressed by the RV/
TLC ratio) and diffusing capacity for carbon monoxide,
and those associations were evident in ex-smokers,
whereas no similar associations were observed in cur-
rent smokers with COPD. This is the first study to our
knowledge that evaluated the associations of EBC pH in
a large cohort of COPD patients, suggesting that it may
represent a biomarker of disease severity in ex-smokers
with COPD.
EBC pH represents a surrogate marker of airway acidi-
fication that has been associated with the presence of
acidification in all levels of the respiratory tract [10].
Airway acidification has been reported to cause bronch-
oconstriction [11], impaired ciliary motility [12],
increased mucous production and viscosity [13], and
Table 1 Demographic and functional characteristics of the study subjects
Controls
n = 112
COPD all
n = 161
COPD ex-smokers
n=8 6
COPD current smokers
n=7 5
Age 65 ± 7 65 ± 10 68 ± 9 62 ± 10
Gender M/F (n) 88/24 122/39 62/24 60/15
Pack-years 61 ± 13 60 ± 14 64 ± 16 64 ± 22
Current/ex-smokers (n) 54/58 75/86
FEV1 (% pred.) 93.8 ± 10.4 53.5 ± 17.7* 48.6 ± 17.3 59.2 ± 16.4
#
FEV1/FVC 83.5 ± 9.8 56.8 ± 10.5* 54.0 ± 10.7 59.9 ± 9.4
#
IC/TLC 0.72 ± 0.13 0.30 ± 0.09* 0.29 ± 0.09 0.30 ± 0.08
RV/TLC 0.35 ± 0.07 0.58 ± 0.11* 0.59 ± 0.12 0.56 ± 0.11
DLCO (%pred.) 87.8 ± 8.5 59.4 ± 22.2* 54.9 ± 23.8 64.1 ± 19.5
†
GOLD COPD stage (I/II/III/IV, n) N/A 16/81/44/20 5/37/28/16 11/44/16/4
Data are presented as mean ± standard deviation, unless otherwise indicated. FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, IC:
Inspiratory capacity, TLC: total lung capacity, RV: residual volume, DLCO: diffusing capacity for carbon monoxide.
* p < 0.001 vs. controls,
#p < 0.001 vs. ex-smokers with COPD,
†p < 0.01 vs. ex-smokers with COPD
Figure 1 EBC pH values in the 4 study groups of the whole
population according to GOLD guidelines. Box-plots represent
median (interquartile ranges). * p < 0.001, # p < 0.01
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development of airway disease.
We have observed that COPD patients with more
severe disease and more severe functional impairment
have lower EBC pH, which may reflect more intense air-
ways inflammation related to the presence of acidifica-
tion. Additionally, ex-smokers had significantly lower
E B Cp Hv a l u e sc o m p a r e dt oc u r r e n ts m o k e r sw i t h
COPD. A possible explanation for the lower EBC pH
values in ex-smokers may be the fact that these patients
had more severe disease compared to current smokers,
as expressed by the significantly lower FEV1,F E V 1/FVC
and DLCO compared to current smokers. Moreover,
there is evidence that airway inflammation is present in
COPD patients even after smoking cessation [15]. Inter-
estingly, in a longitudinal study involving bronchial
biopsies in patients with COPD, the number of sputum
neutrophils, lymphocytes, interleukin-8 and eosinophi-
lic-cationic-protein levels significantly increased at 12
months after successful smoking cessation [15], whereas
in a cross-sectional study with bronchial biopsies, ex-
smokers with COPD had higher CD3+, CD4+, and
plasma cell numbers compared to current smokers [16].
The above data may further explain the significant dif-
ferences in EBC pH levels between current and ex-smo-
kers with COPD.
The presence of significant associations of EBC pH
with functional parameters related to disease severity in
ex-smokers with COPD in our study, in contrast to cur-
rent smokers, is supported by previous findings suggest-
ing that the inflammatory effects of current smoking may
mask the underlying ongoing inflammatory process of
COPD [17]. Smoking causes an acute oxidative burst in
the airways of current smokers [18], and therefore a plau-
sible explanation may be the fact that in current smokers
such associations may have been obscured by current
smoking. A previous study by Borrill et al. failed to show
any associations between EBC pH levels and FEV1 [19].
That study included a significantly smaller number of
COPD patients (n = 36) compared to the present one,
thus it may have not been adequately powered to detect
such an association. Despite that, those authors were able
to find a statistically non-significant trend in ex-smokers
and suggested that a larger study is needed. In the pre-
sent study, in a larger population, we have shown a sig-
nificant association between FEV1 and EBC pH that was
present only in ex-smokers, after the elimination of the
confounding role of continuing smoking.
In this study, we have used as a cut-off point for the
expression of severe hyperinflation, a value of the IC/
Figure 2A 
 
Figure 2B 
Figure 2 EBC pH values according to COPD stages according
to the GOLD guidelines: A. in ex-smokers, B. in current smokers.
Box-plots represent median (interquartile ranges). # p < 0.01, ‡ p<
0.05
Table 2 EBC pH correlations
All Ex-smokers Current smokers
p-value r p-value r p-value r
FEV1 (%pred.) <0.001 0.342 <0.001 0.452 0.313 0.118
FVC (%pred.) 0.001 0.265 <0.001 0.386 0.944 0.008
FEV1/FVC <0.001 0.284 0.002 0.324 0.064 0.215
IC (%pred.) 0.05 0.200 0.025 0.299 0.927 0.015
TLC (%pred.) 0.297 -0.105 0.392 -0.113 0.644 -0.075
IC/TLC 0.173 0.113 0.191 0.153 0.411 0.098
RV (%pred.) 0.046 -0.200 0.044 -0.261 0.462 -0.120
RV/TLC 0.002 -0.303 0.006 -0.350 0.212 -0.204
DLCO (%pred.) <0.001 0.304 <0.001 0.410 0.536 0.074
FEV1: Forced expiratory volume in 1 second, FVC: forced vital capacity, IC:
Inspiratory capacity, TLC: total lung capacity, RV: residual volume, DLCO:
diffusing capacity for carbon monoxide
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express severe hyperinflation and has been associated
with increased mortality in COPD [9]. A recent study
has reported a logarithmic correlation of EBC nitrite
and pulmonary function tests indicating hyperinflation
for COPD patients classified in GOLD class 2 or more.
In contrast, EBC nitrite level was not correlated with
airway obstruction or proinflammatory cytokines [20].
On the basis of this report, it has been recently sug-
gested that the estimation of the extent of hyperinflation
in studies involving COPD patients may lead to the
more proper interpretation of EBC biomarker levels
compared to airflow limitation [21]. In the present
study, we have observed that ex-smokers with COPD
and severe static hyperinflation have lower EBC pH
levels, further supporting a role of EBC pH as a biomar-
ker in this subgroup of patients.
In a similar manner, we have shown that COPD
patients with severe air-trapping and severe impairment
of DLCO, as characterized by the lower quartiles of
those parameters, presented significantly lower EBC pH
values and this was more evident in ex-smokers. It has
been previously reported that in the small airways of
patients with severe COPD there is an increased number
of leucocytes which is correlated with reduced expira-
tory flow, lung hyperinflation and carbon monoxide dif-
fusion impairment, suggesting that the inflammatory
response plays a significant role in the clinical progres-
sion of the disease [22].
The independent association of decreased pH values
with parameters expressing hyperinflation is a novel
finding of the present study, suggesting that this may
represent an inflammatory component related to lung
mechanics. In a well characterized population of COPD
patients, researchers from the GLUCOLD study group
have shown that patients with emphysema present dif-
ferences in sputum cell counts (i.e. higher neutrophil
and lower eosinophil counts), compared to patients with
chronic bronchitis [23]. The patients with hyperinflation
and lower DLCO in our population may well represent
patients with predominance of emphysema. Moreover,
our group has previously shown that EBC pH is inver-
sely related with sputum neutrophil counts [5]. Taken
together, these data may suggest a possible link between
hyperinflation, emphysema and airways acidification.
Although several factors can affect EBC pH, including
the effect of drinking or eating [24], smoking [25,26],
t h ep r e s e n c eo fe x t r a p u l m o n a r yc o m p o n e n t s[ 2 7 ] ,t h e
dilution bias and the purging procedure in order to
achieve the stability of the sample, we tried to overcome
all the above issues by avoiding eating and drinking for
at least 2 hours before collection, by excluding patients
with overt gastroesophageal reflux disease and, finally,
by following the current standardized procedure for pH
collection and measurement [7]. Moreover, the careful
characterization and the large number of COPD patients
included in the present study further support the valid-
ity of our results. Another possible limitation is the
large variation in the measurements of EBC pH that
leads to a large overlap between study groups, and this
may limit the clinical utility of measuring EBC pH in
individual patients. However, we believe that the
Table 3 EBC pH values according to RV/TLC quartiles in our study population
1
st Quartile 2
nd Quartile 3
rd Quartile 4
th Quartile p-value
COPD all RV/TLC ≤0.50 0.50-0.58 0.58-0.66 >0.66
EBC pH 7.52 (6.88, 8.01) 7.19 (6.69, 7.69) 7.27 (7.08, 7.78) 6.93 (5.46, 7.19)
# <0.001
COPD ex-smokers RV/TLC ≤0.52 0.52-0.60 0.60-0.68 >0.68
EBC pH 7.64 (6.88, 7.91) 7.10 (6.68, 7.45) 7.27 (7.08, 7.64) 6.92 (5.79, 7.07)
† 0.006
COPD current smokers RV/TLC ≤0.47 0.47-0.55 0.55-0.63 >0.63
EBC pH 7.48 (7.06, 8.03) 7.36 (6.71, 7.95) 7.23 (6.47, 7.88) 7.13 (5.36, 7.84) 0.398
#p < 0.001 compared to the 1
st quartile
†p < 0.01 compared to the 1
st quartile
Table 4 EBC pH values according to DLCO (%pred.) quartiles in our study population
1
st Quartile 2
nd Quartile 3
rd Quartile 4
th Quartile p-value
COPD all DLCO ≤45.2 45.2-60.0 60.0-72.0 >72.0
EBC pH 7.08 (6.76, 7.50) 7.09 (6.69, 7.24) 7.30(7.13, 7.69)
‡ 7.28 (7.13, 7.28) 0.006
COPD ex-smokers DLCO ≤35.8 35.8-54 54-70.2 >70.2
EBC pH 7.04 (6.07, 7.38) 7.08 (6.79, 7.24) 7.19 (7.03, 7.32) 7.37 (7.19, 7.86)
† 0.004
COPD current smokers DLCO ≤53.8 53.8-67.3 67.3-72.8 >72.8
EBC pH 7.21 (6.71, 7.76) 7.25 (7.09, 7.86) 7.23 (7.11, 7.69) 7.25 (7.10, 7.34) 0.82
‡p < 0.05 compared to the 1
st quartile
†p < 0.01 compared to the 1
st quartile
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presence of hyperinflation, air trapping and/or reduced
diffusing capacity in the present study has significantly
reduced variation and provides possible implications for
clinical application of this biomarker.
In conclusion, in the present study we have shown
that EBC pH is lower in COPD patients compared to
otherwise normal smokers. Moreover, we have shown
that EBC pH is related to disease severity, and to para-
meters expressing airflow limitation, hyperinflation and
air trapping. Those correlations were more robust in ex-
smokers while no significant correlations were found in
current smokers. Our findings suggest that endogenous
airway acidification, as expressed by EBC pH, may be an
indicator of disease severity in ex-smokers with COPD.
In contrast, the above observations may lead to the
hypothesis that current smoking in COPD patients may
influence and alter the results of chronic inflammation,
therefore rendering the interpretation of exhaled bio-
markers more difficult. Longitudinal studies evaluating
the effect of therapeutic interventions targeting lung
hyperinflation and/or air-trapping on EBC pH in ex-
smokers with COPD are justified by our results.
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